Bravo to the Sofinnova Biovelocita team for this milestone! Closing above target at €165M is no small feat – it's strong validation of the strategy and your expertise. Big thanks to Amgen France, Bristol Myers Squibb and Pfizer Ventures, for supporting the next generation of biotech innovation in Europe!
It’s official! Sofinnova Partners Biovelocita II has successfully closed above target at €165M, making it the largest pan-European fund for biotech acceleration. Backed by top pharmas Amgen France, Bristol Myers Squibb and Pfizer Ventures, we’ve already seen over 300 projects and made several key investments to drive transformative innovation in biotechnology. At its core, the Biovelocita team are entrepreneurs who bring decades of company-building experience and dedicated capital to shape the next generation of biotech leaders in Europe. A huge shoutout to our Biovelocita team Maria Gabriella Camboni, Matthieu Coutet, Alex Leech,Zhizhong "Joel" Yao, Marie Duranteau, Cristina Pelizon. Learn more in the press release link in the comments.
Congratulations to the team!
Congratulations!
Congratulations! 🎊
Congratulations Sofinnova Partners team!
Congratulations!!
Complimenti Graziano!
Congrats Graziano and Joel!
Biotech Executive
2wvery cool!